Carmen Coloma-Salvador

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.

Journal: Oncoimmunology

Published: June 19, 2026

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 03, 2025

Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.

Journal: Frontiers in oncology

Published: June 01, 2025

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 30, 2025

Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM).

Journal: European journal of internal medicine

Published: June 12, 2024

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 16, 2024

Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 01, 2023

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 22, 2020

Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 14, 2020

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 11, 2018

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.

Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.

Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM).

Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM).

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group.

Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group.

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas.

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas.

Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population.

Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population.

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.